AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALNY
  4. [Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity

[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Yvonne Greenstreet, Director and CEO of Alnylam Pharmaceuticals (ALNY), reported a mix of equity activity tied to performance compensation and tax withholding on vested awards. On 08/15/2025 she received 14,252 shares upon vesting of 30% of a performance-based stock unit awarded 03/01/2024 after a clinical milestone determination. Following that vesting, multiple automatic sales occurred on 08/18/2025 to satisfy mandatory sell-to-cover tax withholding, reducing her direct holdings from 63,200 to 56,221 shares. The filing also shows 407 shares held indirectly via a managed account and shares acquired under the company 401(k) matching program.

Yvonne Greenstreet, amministratore delegato di Alnylam Pharmaceuticals (ALNY), ha riportato operazioni su azioni derivanti da compensi legati alle performance e dal pagamento delle imposte sulle azioni maturate. Il 15/08/2025 ha ricevuto 14.252 azioni in seguito alla maturazione del 30% di un unit脿 azionaria a prestazione assegnata il 01/03/2024 dopo il raggiungimento di un traguardo clinico. Dopo tale maturazione, il 18/08/2025 sono state effettuate pi霉 vendite automatiche per coprire la ritenuta fiscale obbligatoria, riducendo le sue partecipazioni dirette da 63.200 a 56.221 azioni. La segnalazione indica inoltre 407 azioni detenute indirettamente tramite un conto gestito e azioni acquisite tramite il programma di matching 401(k) dell鈥檃zienda.

Yvonne Greenstreet, directora ejecutiva de Alnylam Pharmaceuticals (ALNY), inform贸 movimientos de acciones relacionados con compensaci贸n por desempe帽o y la retenci贸n fiscal sobre premios que vencieron. El 15/08/2025 recibi贸 14.252 acciones con la maduraci贸n del 30% de una unidad de acciones basada en desempe帽o otorgada el 01/03/2024 tras la consecuci贸n de un hito cl铆nico. Tras esa maduraci贸n, el 18/08/2025 se realizaron varias ventas autom谩ticas para cubrir la retenci贸n fiscal obligatoria, reduciendo sus participaciones directas de 63.200 a 56.221 acciones. La presentaci贸n tambi茅n muestra 407 acciones mantenidas indirectamente a trav茅s de una cuenta gestionada y acciones adquiridas bajo el programa de aportes equivalentes 401(k) de la compa帽铆a.

Alnylam Pharmaceuticals(ALNY) CEO鞚� Yvonne Greenstreet電� 靹标臣 氤挫儊 氚� 毵岅赴霅� 靾橃棳攵勳潣 靹戈笀 鞗愳矞歆曥垬鞕� 甏�霠暅 欤检嫕 瓯半灅 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. 2025-08-15鞐� 鞛勳儊 靹标臣 雼劚鞐� 霐半澕 2024-03-01鞐� 攵�鞐悳 靹标臣 旮半皹 欤检嫕 雼渼鞚� 30%臧� 氩犾姢韺呺悩鞏� 14,252欤茧ゼ 靾橂牴頄堨姷雼堧嫟. 頃措嫻 氩犾姢韺� 鞚错泟 2025-08-18鞐� 頃勳垬 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暅 鞛愲彊 毵る弰臧� 鞐煬 彀 氚滌儩頃橃棳 歆侅爲 氤挫湢 欤检嫕鞚� 63,200欤检棎靹� 56,221欤茧 臧愳唽頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 鞖挫毄瓿勳毳� 韱淀暣 臧勳爲 氤挫湢霅� 407欤检檧 須岇偓 401(k) 毵れ弓 頂勲攴鸽灗鞙茧 旆摑頃� 欤检嫕霃� 旮办灛霅橃柎 鞛堨姷雼堧嫟.

Yvonne Greenstreet, directrice g茅n茅rale d'Alnylam Pharmaceuticals (ALNY), a d茅clar茅 des mouvements d'actions li茅s 脿 des r茅mun茅rations de performance et 脿 la retenue d'imp么t sur des attributions arriv茅es 脿 茅ch茅ance. Le 15/08/2025, elle a re莽u 14 252 actions suite 脿 la lev茅e de 30 % d'une unit茅 d'actions li茅e 脿 la performance attribu茅e le 01/03/2024 apr猫s la r茅alisation d'un jalon clinique. Apr猫s ce vesting, plusieurs ventes automatiques ont eu lieu le 18/08/2025 pour couvrir la retenue d'imp么t obligatoire, r茅duisant ses avoirs directs de 63 200 脿 56 221 actions. Le d茅p么t indique 茅galement 407 actions d茅tenues indirectement via un compte g茅r茅 et des actions acquises dans le cadre du programme de contrepartie 401(k) de la soci茅t茅.

Yvonne Greenstreet, Vorstandsvorsitzende und CEO von Alnylam Pharmaceuticals (ALNY), meldete Aktienbewegungen im Zusammenhang mit leistungsabh盲ngiger Verg眉tung und der Steuerabf眉hrung auf zugewordnete Aktien. Am 15.08.2025 erhielt sie 14.252 Aktien, nachdem 30 % einer performancebasierten Aktienzuteilung vom 01.03.2024 nach Erreichen eines klinischen Meilensteins vesteten. Im Anschluss an diese Vesting-Transaktion kam es am 18.08.2025 zu mehreren automatischen Verk盲ufen zur Begleichung der verpflichtenden Steuerabf眉hrung, wodurch ihr Direktbestand von 63.200 auf 56.221 Aktien sank. Die Meldung weist au脽erdem 407 Aktien aus, die indirekt 眉ber ein verwaltetes Konto gehalten werden, sowie Aktien, die im Rahmen des 401(k)-Matchingprogramms des Unternehmens erworben wurden.

Positive
  • Performance-based PSU vested: 14,252 shares issued upon achievement of a clinical milestone, reflecting compensation tied to operational milestones
  • 401(k) match participation: 407 shares held indirectly from the issuer's 401(k) matching program, indicating use of company benefit plans
Negative
  • Reduction in direct holdings: Direct beneficial ownership decreased from 63,200 to 56,221 shares following mandatory sell-to-cover sales
  • Concentrated sales on one day: Multiple sell transactions on 08/18/2025 at prices from ~$447.53 to $456.00 reduced insider stake

Insights

TL;DR: Routine executive vesting and mandatory sell-to-cover sales; governance signal is standard compensation mechanics, not an extraordinary event.

The filing documents the vesting of a performance-based stock unit tranche tied to a clinical milestone, which was approved by the compensation committee on 08/15/2025 and settled as 14,252 shares. The subsequent clustered sales on 08/18/2025 are described as mandatory sell-to-cover transactions to satisfy statutory tax withholding obligations rather than discretionary disposals. Holdings moved from 63,200 to 56,221 shares directly owned, and an additional 407 shares are held indirectly via a managed account. These actions align with common executive equity compensation settlement practices and do not by themselves indicate a change in corporate strategy or confidence.

TL;DR: Insufficient impact on valuation; transactions are compensation-related and routine.

The reported sales occurred across multiple price ranges, with reported weighted-average prices noted per tranche (examples: $447.98, $449.92, $452.96, up to $456.00). The filing discloses that sales prices represent weighted averages of multiple transactions and that detailed per-transaction breakdowns are available on request. The net effect was a reduction of direct share ownership by 6,979 shares. For investors, this is an expected tax-driven liquidity event following PSU vesting and not a material change to insider ownership trends absent further context.

Yvonne Greenstreet, amministratore delegato di Alnylam Pharmaceuticals (ALNY), ha riportato operazioni su azioni derivanti da compensi legati alle performance e dal pagamento delle imposte sulle azioni maturate. Il 15/08/2025 ha ricevuto 14.252 azioni in seguito alla maturazione del 30% di un unit脿 azionaria a prestazione assegnata il 01/03/2024 dopo il raggiungimento di un traguardo clinico. Dopo tale maturazione, il 18/08/2025 sono state effettuate pi霉 vendite automatiche per coprire la ritenuta fiscale obbligatoria, riducendo le sue partecipazioni dirette da 63.200 a 56.221 azioni. La segnalazione indica inoltre 407 azioni detenute indirettamente tramite un conto gestito e azioni acquisite tramite il programma di matching 401(k) dell鈥檃zienda.

Yvonne Greenstreet, directora ejecutiva de Alnylam Pharmaceuticals (ALNY), inform贸 movimientos de acciones relacionados con compensaci贸n por desempe帽o y la retenci贸n fiscal sobre premios que vencieron. El 15/08/2025 recibi贸 14.252 acciones con la maduraci贸n del 30% de una unidad de acciones basada en desempe帽o otorgada el 01/03/2024 tras la consecuci贸n de un hito cl铆nico. Tras esa maduraci贸n, el 18/08/2025 se realizaron varias ventas autom谩ticas para cubrir la retenci贸n fiscal obligatoria, reduciendo sus participaciones directas de 63.200 a 56.221 acciones. La presentaci贸n tambi茅n muestra 407 acciones mantenidas indirectamente a trav茅s de una cuenta gestionada y acciones adquiridas bajo el programa de aportes equivalentes 401(k) de la compa帽铆a.

Alnylam Pharmaceuticals(ALNY) CEO鞚� Yvonne Greenstreet電� 靹标臣 氤挫儊 氚� 毵岅赴霅� 靾橃棳攵勳潣 靹戈笀 鞗愳矞歆曥垬鞕� 甏�霠暅 欤检嫕 瓯半灅 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. 2025-08-15鞐� 鞛勳儊 靹标臣 雼劚鞐� 霐半澕 2024-03-01鞐� 攵�鞐悳 靹标臣 旮半皹 欤检嫕 雼渼鞚� 30%臧� 氩犾姢韺呺悩鞏� 14,252欤茧ゼ 靾橂牴頄堨姷雼堧嫟. 頃措嫻 氩犾姢韺� 鞚错泟 2025-08-18鞐� 頃勳垬 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暅 鞛愲彊 毵る弰臧� 鞐煬 彀 氚滌儩頃橃棳 歆侅爲 氤挫湢 欤检嫕鞚� 63,200欤检棎靹� 56,221欤茧 臧愳唽頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 鞖挫毄瓿勳毳� 韱淀暣 臧勳爲 氤挫湢霅� 407欤检檧 須岇偓 401(k) 毵れ弓 頂勲攴鸽灗鞙茧 旆摑頃� 欤检嫕霃� 旮办灛霅橃柎 鞛堨姷雼堧嫟.

Yvonne Greenstreet, directrice g茅n茅rale d'Alnylam Pharmaceuticals (ALNY), a d茅clar茅 des mouvements d'actions li茅s 脿 des r茅mun茅rations de performance et 脿 la retenue d'imp么t sur des attributions arriv茅es 脿 茅ch茅ance. Le 15/08/2025, elle a re莽u 14 252 actions suite 脿 la lev茅e de 30 % d'une unit茅 d'actions li茅e 脿 la performance attribu茅e le 01/03/2024 apr猫s la r茅alisation d'un jalon clinique. Apr猫s ce vesting, plusieurs ventes automatiques ont eu lieu le 18/08/2025 pour couvrir la retenue d'imp么t obligatoire, r茅duisant ses avoirs directs de 63 200 脿 56 221 actions. Le d茅p么t indique 茅galement 407 actions d茅tenues indirectement via un compte g茅r茅 et des actions acquises dans le cadre du programme de contrepartie 401(k) de la soci茅t茅.

Yvonne Greenstreet, Vorstandsvorsitzende und CEO von Alnylam Pharmaceuticals (ALNY), meldete Aktienbewegungen im Zusammenhang mit leistungsabh盲ngiger Verg眉tung und der Steuerabf眉hrung auf zugewordnete Aktien. Am 15.08.2025 erhielt sie 14.252 Aktien, nachdem 30 % einer performancebasierten Aktienzuteilung vom 01.03.2024 nach Erreichen eines klinischen Meilensteins vesteten. Im Anschluss an diese Vesting-Transaktion kam es am 18.08.2025 zu mehreren automatischen Verk盲ufen zur Begleichung der verpflichtenden Steuerabf眉hrung, wodurch ihr Direktbestand von 63.200 auf 56.221 Aktien sank. Die Meldung weist au脽erdem 407 Aktien aus, die indirekt 眉ber ein verwaltetes Konto gehalten werden, sowie Aktien, die im Rahmen des 401(k)-Matchingprogramms des Unternehmens erworben wurden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Greenstreet Yvonne
(Last) (First) (Middle)
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 A(1) 14,252 A $0.0 63,200 D
Common Stock 08/18/2025 S(2) 194 D $447.98(3) 63,006 D
Common Stock 08/18/2025 S(2) 450 D $449.92(4) 62,556 D
Common Stock 08/18/2025 S(2) 195 D $450.92(5) 62,361 D
Common Stock 08/18/2025 S(2) 514 D $451.99(6) 61,847 D
Common Stock 08/18/2025 S(2) 1,646 D $452.96(7) 60,201 D
Common Stock 08/18/2025 S(2) 2,716 D $454.04(8) 57,485 D
Common Stock 08/18/2025 S(2) 1,204 D $454.84(9) 56,281 D
Common Stock 08/18/2025 S(2) 60 D $455.82(10) 56,221 D
Common Stock 407 I by Managed Account(11)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.
2. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.
3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
7. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
8. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
9. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
10. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
11. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
By: Brett Budzinski, Attorney-in-Fact For: Yvonne Greenstreet 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What triggered the issuance of 14,252 shares to Yvonne Greenstreet?

The shares were issued upon vesting of 30% of a performance-based stock unit granted 03/01/2024 after a clinical milestone was determined by the People, Culture and Compensation Committee on 08/15/2025.

Why were shares sold on 08/18/2025 according to the Form 4 for ALNY?

The filing states the shares were automatically sold pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations that became due upon vesting and settlement.

How did Greenstreet's direct ownership change after these transactions?

Direct beneficial ownership reported moved from 63,200 shares to 56,221 shares following the reported sales and issuance.

Are the reported sale prices exact per-trade amounts?

The filing reports weighted average sales prices for groups of transactions (ranges provided) and notes the reporting person can provide breakdowns of shares sold at each price upon request.

Does the Form 4 show any indirect holdings for Yvonne Greenstreet?

Yes, the filing reports 407 shares held indirectly via a managed account and additional shares acquired under the issuer 401(k) matching contribution program.
Stock ALNY logo
Alnylam Pharmaceuticals Inc

NASDAQ:ALNY

ALNY Rankings

#255 Ranked by Market Cap
N/A Ranked by Dividends

ALNY Latest News

Aug 31, 2025
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran鈥檚 Long-Term Cardiovascular Benefit in ATTR-CM
Aug 30, 2025
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
Aug 30, 2025
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
Aug 27, 2025
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 11, 2025
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

ALNY Latest SEC Filings

Aug 29, 2025
[144] Alnylam Pharmaceuticals, Inc. SEC Filing
Aug 19, 2025
[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity

ALNY Stock Data

59.53B
125.76M
3.8%
99.09%
2.47%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE